SPY314.38-1.80 -0.57%
DIA257.24-3.48 -1.33%
IXIC10,547.75+55.25 0.53%

Intercept Receives Complete Response Letter from FDA for Obeticholic Acid for the Treatment of Fibrosis Due to NASH, FDA States That Predicted Benefit Remains Uncertain

Benzinga · -